Abstract:The biological efficacy of half-sandwich platinum group organometallic complexes of the formula [(eta(5)-Cp-x)/(eta(6)arene)M(XY)Cl](0/+) (XY = bidentate ligands; Cp-x = functionalized cyclopentadienyl; M = Ir, Rh, Ru, Os) has received considerable attention due to the significance of the metal center, chelating ligand, and Cp-x/arene moieties in defining their anticancer potency and selectivity. With a facile access to the BIAN-derived imine-amine ligands using alkylaluminum as the reductant, we herein described the preparation and characterization of 16 half-sandwich Ir(III), Rh(III), and Ru(II) complexes chelating the hybrid sp(2)N/sp(3)-N donor ligand. A nonplanar five-member metallacycle was confirmed by X-ray single-crystal structures of Ir1-Ir3, Ir7, Rh1, Ru1, and Ru4. The attempt to prepare imine-amido complexes using a base as the deprotonating agent led to the mixture of imine-amine complexes, within which the leaving group Cl- was displaced, and 16-electron imine-amido complexes without Cl-. The half-sandwich imine-amine complexes in this system underwent rapid hydrolysis in aqueous solution, exhibited weak photoluminescence, and showed the ability of binding to CT-DNA and BSA. The cytotoxicity of all imine-amine complexes against A549 lung cancer cell lines, HeLa cervical cancer cell lines, and 4T1 mouse breast cancer cells was determined by an MTT assay. The IC50 values of these complexes were in a range of 5.71-67.28 mu M. Notably, most of these complexes displayed improved selectivity toward A549 cancer cells versus noncancerous BEAS-2B cells in comparison with the corresponding alpha-diimine complexes chelating the sp(2)-N/sp(2)-N donor ligand, which have been shown no selectivity in our previous report. The anticancer selectivity of these complexes appeared to be related to the redox-based mechanism including the catalytic oxidation of NADH to NAD(+), reactive oxygen species (ROS) generation, and depolarization of the mitochondrial membrane. Further, inducing apoptosis of these complexes in A549 cancer cells and BEAS-2B normal cells also correlated with their anticancer selectivity, indicating the apoptosis mode of cell death in this system. In addition, these complexes could enter A549 cells via energy-dependent pathway and were able to impede the in vitro migration of A549 cells.

Half-sandwich Iridium(III) Complexes with Triphenylamine-Substituted Dipyridine Frameworks and Bioactivity Applications

Triphenylamine-Appended Half-Sandwich Iridium(III) Complexes and Their Biological Applications.

Half-sandwich Iridium(iii) Complexes with Α-Picolinic Acid Frameworks and Antitumor Applications.

Half-sandwich Iridium III N-heterocyclic carbene antitumor complexes and biological applications.

Half-sandwich Iridium(III) Benzimidazole-Appended Imidazolium-Based N-heterocyclic Carbene Complexes and Antitumor Application.

Half-sandwich Iridium N-heterocyclic Carbene Anticancer Complexes

Lysosome-Targeted Phosphine-Imine Half-Sandwich Iridium(III) Anticancer Complexes: Synthesis, Characterization, and Biological Activity

Lysosome-Targeted Potent Half-Sandwich Iridium(Iii) Alpha-Diimine Antitumor Complexes

Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C∧N-Chelated and Pyridine Ligands.

Potent Half-Sandwich Iridium(III) and Ruthenium(II) Anticancer Complexes Containing a P^O-Chelated Ligand

Imidazole and Benzimidazole Modified Half-Sandwich Iridium III N -Heterocyclic Carbene Complexes: Synthesis, Anticancer Application, and Organelle Targeting.

Preparation and Bioactivity of Iridium(III) Phenanthroline Complexes with Halide Ions and Pyridine Leaving Groups

Triphenylamine and carbazole‐modified iridiumIII 2‐phenylpyridine complexes: Synthesis, anticaner application and targeted research

Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.

In Vitro and In Vivo of Triphenylamine-Appended Fluorescent Half-Sandwich Iridium(III) Thiosemicarbazones Antitumor Complexes

Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.

Organometallic Half-Sandwich Iridium Anticancer Complexes

Design and Anticancer Behaviour of Cationic/neutral Half-Sandwich Iridium (III) Imidazole-Phenanthroline/phenanthrene Complexes

Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid Sp2-N/sp3-n Donor Ligands to Achieve Improved Anticancer Selectivity.

Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.

Synthesis and Antineoplastic Applications of TPE Appended Organometallic Iridium(III) Complexes.